News

Labcorp Holdings Inc. Declares Cash Dividend of $0.72 Per Share

Fintel·16:37LH▲+0.4%

Labcorp Prepares to Report Q3 Earnings: What's in the Cards?

LH's Q3 earnings may benefit from strong diagnostics demand, specialty testing expansion and acquisitions, with revenues projected to grow 5.7%.

Yahoo·08:28LH▲+0.4%

Labcorp Declares Quarterly Dividend

Labcorp Holdings Inc. (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today that its Board of Directors has declared a cash dividend of $0.72 per share of common stock. The dividend will be payable on December 11, 2026, to stockholders of record as of the close of business on November 24, 2026.

Yahoo·06:50LH▲+0.4%

Myriad Genetics Offloads Struggling Prenatal Unit for $210 Million to Labcorp

Labcorp will purchase Myriad Genetics' prenatal testing business for $210 million in cash, projecting $160 million in year-one revenue.

Benzinga·08:37LH▲+0.4%

Myriad Genetics and Labcorp Announce Definitive Agreement for Myriad to Sell Prenatal Health Testing Business to Labcorp

Transaction to benefit patients through expanded access and support Myriad’s strategic prioritiesSALT LAKE CITY and BURLINGTON, N.C., Oct. 20, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, and Labcorp (NYSE: LH), a global leader in innovative and comprehensive laboratory services, today announce they have entered into a definitive agreement for Myriad to sell its Prenatal Health testing business, which includes the

Yahoo·08:30LH

Myriad Genetics To Sell Its Prenatal Health Testing Business, Including Prequel, Foresight, SneakPeek And FirstGene Tests, To Labcorp For $210M In Cash Plus Inventory Value

When complete, the transaction is expected to provide more patients and physicians with expanded access to Labcorp’s comprehensive, high-quality laboratory services, convenient patient service center network, robust

Benzinga·04:35LH▲+0.4%

OPKO Health to Sell Select BioReference Assets to Labcorp for $722M

OPK's $722M BioReference asset sale to Labcorp, with a potential $150M earnout, aims to sharpen its biopharma focus and expand access to the 4Kscore Test.

Yahoo·10:20LH▲+0.4%

Labcorp (LH) Stock Looks In Step With Its Cash Flow Outlook

Labcorp Holdings has delivered a strong share price run in recent years, so the key issue now is whether the current US$325.07 level is properly supported by the cash it can generate. With investors already sitting on sizeable gains, the question is how closely the recent price action lines up with the company’s underlying cash flow profile. Over the past 3 years the stock has returned 68.8%. This puts real weight on whether that gain aligns with the cash the business is expected to produce...

Yahoo·21:15LH▲+0.4%

Q2 Earnings Outperformers: Labcorp (NYSE:LH) And The Rest Of The Testing & Diagnostics Services Stocks

Wrapping up Q2 earnings, we look at the numbers and key takeaways for the testing & diagnostics services stocks, including Labcorp (NYSE:LH) and its peers.

Yahoo·12:08LH0.4%

OPKO Health Sheds Diagnostics Businesses in Major Labcorp Deal

OPKO Health jumps 18% and Labcorp trades higher as LH acquires BioReference Health assets in an $872M deal.

Benzinga·07:41LH▲+0.4%

Labcorp Enters into Agreement with OPKO Health to Acquire Select Assets of BioReference Health

Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, and OPKO Health, Inc. (Nasdaq: OPK), a multinational biopharmaceutical company, announced today that they have entered into an agreement for Labcorp to acquire select assets of BioReference Health, LLC, a wholly owned subsidiary of OPKO Health.

Yahoo·07:30LH▲+0.4%

UPDATE: Labcorp Agrees To Acquire Select Assets Of OPKO Health's BioReference Health Subsidiary For $722M In Cash, Up To Additional $150M In Earnout On Revenue

Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, and OPKO Health, Inc. (NASDAQ:OPK), a multinational biopharmaceutical company, announced today that they have entered into an

Benzinga·04:21LH▲+0.4%

Labcorp Agrees To Acquire Select Assets Of OPKO Health's BioReference Health Subsidiary For $722M In Cash, Up To Additional $150M In Earnout On Revenue

Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, and OPKO Health, Inc. (NASDAQ:OPK), a multinational biopharmaceutical company, announced today that they have entered into an

Benzinga·03:33LH▲0.4%

Labcorp and Arianna Huffington's Thrive Global Collaborate to Launch Thrive 5 Health Test

Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced the launch of the Thrive 5 Health Test, the first lab test offered in collaboration with Arianna Huffington's behavior change technology company, Thrive Global. Available through Labcorp OnDemand, the offering pairs trusted health insights from Labcorp with Thrive Global's behavior change approach, giving consumers a better understanding of their health and practical ways to improve it.

Yahoo·08:00LH▲+0.4%

Labcorp to Announce Third Quarter 2026 Financial Results on October 28, 2026

Labcorp Holdings Inc. (NYSE: LH), a global leader of innovative and comprehensive laboratory services, will release its financial results for the third quarter of 2026 before the market opens on Wednesday, October 28, 2026. The company will host a webcast beginning at 9:00 a.m. ET that day to discuss the results. The earnings press release and accompanying financial information will be posted on the "News & Events" section of the Labcorp Investor Relations website at https://ir.labcorp.com. A li

Yahoo·08:30LH▲+0.4%

Is This the Right Time to Add Labcorp Stock to Your Portfolio?

LH expands specialty testing and consumer services through acquisitions, partnerships and AI, while reimbursement and cost risks remain.

Yahoo·07:44LH▲+0.4%

Labcorp: The CMS Selloff Represents An Excellent Opportunity - Strong Buy

Labcorp dives on CMS 2027 Medicare lab-payment cuts; see why the selloff may be overdone, and the downside capped and why it’s a strong buy of LH stock—read now.

SeekingAlpha·10:58LH▲+0.4%

Labcorp Holdings (LH) Eyes Acquisitions And Lab Tech Investment After 2026 Investor Day

Labcorp Holdings (NYSE:LH) used its 2026 Investor Day to outline a push into targeted acquisitions and new lab technologies. Management emphasized capital deployment toward advanced lab management systems and expanded digital experiences for patients and providers. The company highlighted plans to integrate acquired platforms with its existing diagnostic infrastructure to streamline operations and data handling. Labcorp's renewed focus on acquisitions and digital lab tools only tells part of...

Yahoo·07:13

Is Labcorp Holdings Stock Outperforming the Dow?

Labcorp Holdings stock has outpaced the Dow this year, and analysts remain bullish about its prospects.

Yahoo·02:16LH▲+0.4%

Labcorp's Future Driven By Clinical Testing Demand, Despite Impact From Medicare Cuts

Labcorp Holdings Inc. upgraded to Buy: resilient diagnostics demand, strong Q2, modest valuation and new tests offset Medicare cuts. Click for this LH update.

SeekingAlpha·13:53LH▲+0.4%

Labcorp Reaffirms 2026–2029 Long-Term Outlook Following CMS Preliminary Medicare Payment Rate Release; Expects Compound Annual Adj EPS Growth Of 8.5%-11.5% In 2026-2029

On September 21, 2026, the Centers for Medicare & Medicaid Services ("CMS") released preliminary Clinical Laboratory Fee Schedule payment rates applicable from 2027 through 2029 pursuant to the Protecting

Benzinga·12:46LH▲0.4%

Quest Diagnostics, Labcorp Shares Fall as Medicare Signals Cuts in Payment Rates for Lab Services

Quest Diagnostics (DGX) and Labcorp (LH) shares fell in Tuesday premarket trading after the Centers

Yahoo·08:46LH▲+0.4%

Stocks making the biggest moves midday: Lennar, Capri, Vicor, Amgen & more

These are the stocks posting the largest moves midday.

CNBC·08:18

Premarket movers: Quest, Labcorp hit by CMS cuts

Investing.com - U.S. stock index futures steadied on Tuesday, following a strong session on Wall Street that saw the benchmark S&P 500 post its best day since August, helped by gains in artificial intelligence-linked stocks.

Yahoo·07:55LH▲+0.4%

2 of Wall Street’s Favorite Stocks to Target This Week and 1 Facing Challenges

Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptical because analysts face institutional pressures that can sometimes lead to overly optimistic forecasts.

Yahoo·03:08

Labcorp Holdings Inc. (LH) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Labcorp Holdings Inc. (LH) Morgan Stanley 24th Annual Global Healthcare Conference September 15, 2026 11:30 AM EDTCompany ParticipantsAdam Schechter -...

SeekingAlpha·10:31LH▲+0.4%

Labcorp Bets Big on AI, Specialty Testing to Drive Growth Through 2029

Labcorp Holdings on Thursday presented a comprehensive growth strategy and long-term financial forecast during its 2026 Investor Day. The health care company emphasized its innovation roadmap, technological advancements and solid financial expectations for the coming years. Reaffirming Financial Targets The...

Yahoo·15:30LH▲+0.4%

1 Mid-Cap Stock with Competitive Advantages and 2 That Underwhelm

Mid-cap stocks often strike the right balance between having proven business models and market opportunities that can support $100 billion corporations. However, they face intense competition from scaled industry giants and can be disrupted by new innovative players vying for a slice of the pie.

Yahoo·12:03

Labcorp Holdings Inc. (LH) Analyst/Investor Day - Slideshow

2026-09-12. The following slide deck was published by Labcorp Holdings Inc.

SeekingAlpha·15:13LH▲+0.4%

Deal Dispatch: Bending Spoons Acquires Miro For $1.35B, Kinetik Up For Sale, LIV Golf Bankruptcy

Read this week's top deal updates, including Bending Spoons' Miro deal, Chime's Stride Bank purchase, and the LIV Golf bankruptcy.

Benzinga·09:10

UBS Maintains Buy on Labcorp Holdings, Raises Price Target to $380

UBS analyst Kevin Caliendo maintains Labcorp Holdings (NYSE:LH) with a Buy and raises the price target from $361 to $380.

Benzinga·06:11LH▲+0.4%

Barclays Maintains Equal-Weight on Labcorp Holdings, Raises Price Target to $330

Barclays analyst Luke Sergott maintains Labcorp Holdings (NYSE:LH) with a Equal-Weight and raises the price target from $320 to $330.

Benzinga·05:45LH▲+0.4%

OPK Climbs 12.4% in the Past Month: Can the Stock Rally Keep Going?

OPKO Health's 12.4% monthly gain is backed by narrower losses and better margins, though profitability and clinical execution remain key risks.

Yahoo·13:35

Labcorp and NACHC Launch Strategic Alliance to Strengthen Health Center Leadership and Advance Community Health

Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, and the National Association of Community Health Centers (NACHC) today announced a strategic alliance to strengthen leadership development, support practice improvement and advance community health initiatives across the nation's Community Health Center (CHC) network. As part of the collaboration, the organizations are launching the NACHC Leadership Exchange for Chief Medical Officers, designed to support cu

Yahoo·08:00LH▲+0.4%

Labcorp And NACHC Announce Strategic Alliance To Support Practice Improvement And Advance Community Health Initiatives Across Community Health Center Network

Collaboration will support leadership development, practice improvement and innovation across the nation's Community Health CentersBURLINGTON, N.C. and BETHESDA, Md., Aug. 18, 2026 /PRNewswire/ -- Labcorp (NYSE:LH),

Benzinga·03:08

Labcorp to Host Investor Day on September 10, 2026

Labcorp Holdings Inc. (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced it will host an Investor Day on Thursday, September 10, 2026, from 9 a.m. to noon ET.

Yahoo·09:00LH▲+0.4%

Labcorp CEO Adam Schechter Sells 4,669 Shares for $1.5 Million

Schechter maintains a $33 million stake after this pre-scheduled sale under a Rule 10b5-1 plan.

Yahoo·17:35LH▲+0.4%

Is Labcorp Holdings (LH) Fully Priced Following Oncology Approvals And Raised Outlook?

Labcorp Holdings (LH) is in focus after a series of oncology diagnostics approvals and launches, including the PGDx elio tissue complete CDx for advanced melanoma and nationwide access to Roche's VENTANA PTEN RxDx Assay for prostate cancer. See our latest analysis for Labcorp Holdings. Labcorp Holdings has attracted more attention in recent months, with oncology diagnostics approvals and stronger earnings updates sitting alongside a 30 day share price return of 16.48% and a 1 year total...

Yahoo·13:08LH▲0.4%

Did Stronger Guidance, Buybacks and New Oncology Tests Just Shift Labcorp Holdings' (LH) Investment Narrative?

In late July and early August 2026, Labcorp reported higher second-quarter and year-to-date earnings, raised its 2026 revenue growth guidance, completed a large share repurchase program, and expanded its precision oncology offering by making Roche's FDA-approved VENTANA PTEN (SP218) RxDx Assay available nationwide to help guide prostate cancer treatment decisions. Together with the recent FDA approval of its PGDx elio tissue complete CDx for advanced melanoma, these developments reinforce...

Yahoo·01:41LH▲+0.4%

Labcorp Announces FDA Approval of Companion Diagnostic Supporting Patients with Advanced Melanoma

Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced that the U.S. Food and Drug Administration (FDA) has approved Labcorp's PGDx elio® tissue complete CDx as a companion diagnostic to help identify patients with advanced melanoma with certain BRAF variants who may benefit from treatment with FDA-approved targeted therapiesi.

Yahoo·07:00LH▲+0.4%